Download PDF
Thromb Haemost 1984; 51(03): 396-397
DOI: 10.1055/s-0038-1661110
Original Article
Schattauer GmbH Stuttgart

Modulation of Rapid Plasminogen Activator Inhibitor in Plasma by Stanozolol

J H Verheijen
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
D C Rijken
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
G T G Chang
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
F E Preston
1   The University Dept. of Haematology, Royal Hallamshire Hospital, Sheffield, U.K.
,
C Kluft
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 14 December 1983

Accepted 14 April 1984

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Fibrinolytic activity in plasma euglobulin fractions can be increased by oral administration of stanozolol. This increase is not caused by increased synthesis or release of tissue-type plasminogen activator. A decreased level of fast acting t-PA inhibition is very probably the cause of the higher activity. These results suggest that this inhibition has a regulatory role on fibrinolysis in vivo.

Keywords

Plasminogen activator inhibition - Plasma - Regulation of fibrinolysis - Stanozolol
 

  • References

  • 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedSearch in Google Scholar
  • 2 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedSearch in Google Scholar
  • 3 Gader AM A, DaCosta J, Cash JG. A new vasopressin analogue and fibrinolysis. Lancet 1973; 2: 1417-1418
    PubMedSearch in Google Scholar
  • 4 Brommer EJ P, Barrett-Bergshoeff MM, Allen RA, Schicht I, Bertina RM, Schalekamp MA D H. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients. Analysis of responders and non-responders. Thromb Haemostas 1982; 48: 156-161
    PubMedSearch in Google Scholar
  • 5 Davidson JF, Lockhead M, McDonald GA, McNicol GP. Fibrinolytic enhancement by stanozolol: a double blind trial. Br J Haematol 1972; 22: 543
    CrossrefPubMedSearch in Google Scholar
  • 6 Walker ID, Davidson JF. Long-term fibrinolytic enhancement with anabolic steroid therapy: a five year study. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (Eds.) Raven Press; New York: 1978. 3 491
    Search in Google Scholar
  • 7 Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, Greaves M, Verheijen JH, Dooijewaard G. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemostas 1984; 51: 157-164
    PubMedSearch in Google Scholar
  • 8 Rijken DC, Sens EH C, van Hinsbergh VW M. An enzyme immunoassay for human tissue-type plasminogen activator. Thromb Haemostas 1983; 50: 269 (Abstr.)
    PubMedSearch in Google Scholar
  • 9 Verheijen JH, Chang GT G, Mullaart E. Inhibition of extrinsic (tissue-type) plasminogen activator by human plasma: Evidence for the occurrence of a fast-acting inhibitor. Thromb Haemostas 1983; 50: 294 (Abstr.)
    PubMedSearch in Google Scholar
  • 10 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedSearch in Google Scholar
  • 11 Rijken DC, Wijngaards G, Zaal-de JongM, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta 1979; 580: 140-153
    CrossrefPubMedSearch in Google Scholar
  • 12 Kluft C, van Wezel AL, van der Velden CA M, Emeis JJ, Verheijen JH, Wijngaards G. Large scale production of extrinsic (tissue-type) plasminogen activator from human melanoma cells. Advances in biotechnological processes. Mizrahi A, van Wezel AL. (Eds.) A. R. Liss Inc; New York: 1983. 2 97-110
    Search in Google Scholar
  • 13 Kruithof EK O, Ransijn A, Bachmann F. Inhibition of tissue plasminogen activator (TA) by human plasma. Haemostasis 1982; 11 (S1) 60 (Abstr.)
    PubMedSearch in Google Scholar
  • 14 Chmielewska J, Rånby M, Wiman B. Determination of tissue plasminogen activator in plasma. Evidence for a rapid inhibitor Thromb Haemostas 1983; 50: 193 (Abstr.)
    PubMedSearch in Google Scholar
  • 15 Kruithof EK O, Ransijn A, Tran-Thang C, Bachmann F. Characteristics of a fast acting inhibitor of plasminogen activator in human plasma. Thromb Haemostas 1983; 50: 193 (Abstr.)
    PubMedSearch in Google Scholar
  • 16 Philips M, Thorsen S. Binding of plasminogen activator (PA) to a component (X) of endothelial cells (EC) may explain the 95,000-Mr PA in human plasma. Thromb Haemostas 1983; 50: 193 (Abstr.)
    PubMedSearch in Google Scholar
  • 17 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392
    PubMedSearch in Google Scholar